Abstract
It is the goal of pharmacogenomics in psychiatry to establish predictive relationships between polymorphisms of candidate genes and therapeutic response to drug treatment. Polymorphisms of candidate genes related to drug mechanisms and pathophysiology of illness and defined clinical phenotype are the foundations for pharmacogenomic studies. Pharmacogenomic studies of antipsychotic response have focused on polymorphisms of genes for dopamine and serotonin receptors with most positive results reported for polymorphisms of genes of the 5HT2a and 5HT2c serotonin receptor subtypes. Although the goal of establishing individualized medicine predicated on an individual patient's genetic code has yet to be achieved, the fundamentals are now in place for second-generation investigation and more application to health care.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 303-321 |
| Number of pages | 19 |
| Journal | Psychiatric Clinics of North America |
| Volume | 26 |
| Issue number | 2 |
| DOIs | |
| State | Published - Jun 2003 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Psychiatry and Mental health
Cite this
Pharmacogenomics of psychiatric drug treatment. / Pickar, David.
In: Psychiatric Clinics of North America, Vol. 26, No. 2, 06.2003, p. 303-321.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Pharmacogenomics of psychiatric drug treatment
AU - Pickar, David
PY - 2003/6
Y1 - 2003/6
N2 - It is the goal of pharmacogenomics in psychiatry to establish predictive relationships between polymorphisms of candidate genes and therapeutic response to drug treatment. Polymorphisms of candidate genes related to drug mechanisms and pathophysiology of illness and defined clinical phenotype are the foundations for pharmacogenomic studies. Pharmacogenomic studies of antipsychotic response have focused on polymorphisms of genes for dopamine and serotonin receptors with most positive results reported for polymorphisms of genes of the 5HT2a and 5HT2c serotonin receptor subtypes. Although the goal of establishing individualized medicine predicated on an individual patient's genetic code has yet to be achieved, the fundamentals are now in place for second-generation investigation and more application to health care.
AB - It is the goal of pharmacogenomics in psychiatry to establish predictive relationships between polymorphisms of candidate genes and therapeutic response to drug treatment. Polymorphisms of candidate genes related to drug mechanisms and pathophysiology of illness and defined clinical phenotype are the foundations for pharmacogenomic studies. Pharmacogenomic studies of antipsychotic response have focused on polymorphisms of genes for dopamine and serotonin receptors with most positive results reported for polymorphisms of genes of the 5HT2a and 5HT2c serotonin receptor subtypes. Although the goal of establishing individualized medicine predicated on an individual patient's genetic code has yet to be achieved, the fundamentals are now in place for second-generation investigation and more application to health care.
UR - http://www.scopus.com/inward/record.url?scp=0038586364&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0038586364&partnerID=8YFLogxK
U2 - 10.1016/S0193-953X(02)00109-0
DO - 10.1016/S0193-953X(02)00109-0
M3 - Article
C2 - 12778835
AN - SCOPUS:0038586364
VL - 26
SP - 303
EP - 321
JO - Psychiatric Clinics of North America
JF - Psychiatric Clinics of North America
SN - 0193-953X
IS - 2
ER -